IL6 and infection: Despite several drugs available on the market, including anti-TNF-α (infliximab, etanercept), anti-IL-6 (tocilizumab), anti-JAK (tofacitinib), and anti-CD20 (rituximab), their effectiveness is limited to subgroups of patients, while their administration is associated with serious side effects such as ulcers, fatigue, reduced immunity to infections, and osteoporosis (78, 79).